JPMorgan Chase & Co. Purchases 14,280 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

JPMorgan Chase & Co. increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 176.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,351 shares of the company’s stock after purchasing an additional 14,280 shares during the period. JPMorgan Chase & Co.’s holdings in NewAmsterdam Pharma were worth $371,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Sei Investments Co. grew its position in NewAmsterdam Pharma by 49.1% in the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after acquiring an additional 8,087 shares in the last quarter. Millennium Management LLC boosted its stake in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after buying an additional 217,902 shares during the period. abrdn plc lifted its holdings in shares of NewAmsterdam Pharma by 69.8% in the 3rd quarter. abrdn plc now owns 129,060 shares of the company’s stock worth $2,142,000 after acquiring an additional 53,060 shares during the last quarter. TimesSquare Capital Management LLC boosted its stake in shares of NewAmsterdam Pharma by 3.7% during the 3rd quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company’s stock worth $4,237,000 after purchasing an additional 9,160 shares during the period. Finally, Lisanti Capital Growth LLC bought a new position in NewAmsterdam Pharma during the 3rd quarter valued at about $700,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NAMS. HC Wainwright restated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $41.60.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock opened at $20.78 on Thursday. NewAmsterdam Pharma has a 52 week low of $15.19 and a 52 week high of $27.29. The firm has a 50 day moving average of $23.48 and a two-hundred day moving average of $19.96.

Insider Activity

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the completion of the transaction, the insider now owns 11,150,461 shares in the company, valued at approximately $283,110,204.79. The trade was a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 446,730 shares of company stock valued at $11,438,695. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.